[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.121.230. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 21, 1984

Ranitidine and Cimetidine

Author Affiliations

Merck Sharp & Dohme Research Laboratories West Point, Pa
Smith Kline & French Laboratories Philadelphia

JAMA. 1984;252(23):3252-3253. doi:10.1001/jama.1984.03350230014017
Abstract

To the Editor.—  It is to be expected that a review of the recently approved H2-receptor antagonist, ranitidine, include reference to cimetidine, the pioneer drug in this group.We believe, however, that in so doing, in his recent article on ranitidine appearing in The Journal, Strum1 has rendered a disservice not only to cimetidine but to the readers as well. The data he has chosen to present, plus his selection of contrasts and comparisons of the two drugs, have resulted in an unfairly balanced article to the detriment of cimetidine and one that is misleading in regard to both drugs. This imbalance is most prominent in the sections of the article dealing with efficacy and adverse effects.In the "Pharmacokinetics" section, Dr Strum's discussion of a 100-mg dose of ranitidine seems irrelevant inasmuch as ranitidine is available only as a 150-mg tablet. He does not mention whether the data

×